Evgen Pharma plc
("Evgen" or the "Company")
Result of AGM and Investor Presentation
Evgen Pharma plc (AIM: EVG), a clinical stage drug development company developing sulforaphane based medicines for the treatment of multiple diseases, held its AGM yesterday, on 21 July 2022, where all resolutions were passed. The AGM voting results are available on the Company's website HERE.
Following the completion of the AGM, Dr Huw Jones, the CEO and Richard Moulson, CFO held a virtual presentation for investors via the Investor Meet platform. The presentation was recorded and can be viewed HERE.
-Ends-
Enquiries:
| Evgen Pharma plc | |
| FinnCap (Nominated Advisor and Broker) | +44 20 7220 0500 |
| Instinctif Partners Melanie Toyne-Sewell / Rozi Morris / Agnes Stephens / Adam Loudon | +44 207 457 2020 |
Notes to Editors
About Evgen Pharma plc
Evgen Pharma is a clinical stage drug development company developing sulforaphane based medicines for the treatment of multiple diseases. The Company's core technology is Sulforadex®, a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane.
The Company's lead asset, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin and has undergone clinical trials for oestrogen-positive (ER+) metastatic breast cancer. It will be entering the clinic in glioma/glioblastoma later in 2022. In September 2021 the FDA granted Orphan Drug status to SFX-01 in malignant glioma.
The Company also has a wide number of collaborations with leading academic centres in the UK, Europe and AsiaPac as part of the continuing strategy to build the data set of safety and efficacy around the compound. With respect to non-core areas, Evgen signed an outlicensing deal with JuvLife, the dietary products and functional foods division of Juvenescence Ltd, for the development of a naturally-sourced sulforaphane nutritional health supplement, stabilised using Evgen's Sulforadex® technology.
The Company commenced operations in January 2008 and has its headquarters and registered office at Alderley Park, Cheshire. It joined the AIM market of the London Stock Exchange in October 2015 and trades under the ticker symbol EVG.
For further information, please visit: www.evgen.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.